Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in:

03.08.2017 | Vitreoretinal Disorders and Vitrectomy

Intravitreal Actilyse® injection to induce posterior vitreous detachment in eyes with recent onset of retinal vein occlusion

A retrospective evaluation

verfasst von: Thomas Bertelmann, Stefan Strodthoff, Walter Sekundo, Stefan Mennel

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Summary

Purpose

To assess the efficacy of intravitreally injected tissue plasminogen activator (t-PA, Alteplase [Actilyse®]) to induce posterior vitreous detachment (PVD) in eyes with recent onset of retinal vein occlusion (RVO).

Methods

Retrospective patient chart analysis.

Results

Nine eyes were included thereof 4 eyes (44%) with central (CRVO) and 5 eyes (56%) with branch RVO (BRVO). One week after injection none of the eyes treated showed PVD formation. After 12 months one patient (17%) developed partial PVD and two patients (33%) demonstrated complete PVD. All eyes developing (partial) PVD after one year suffered from BRVO. Mean best corrected visual acuity (BCVA) increased from 0.35 to 0.45 after one week (p = 0.401) and further to 1.0 after 12 months (p = 0.042). There was an overall significant gain in mean BCVA development after 12 months (p = 0.015). Mean central retinal thickness decreased from 572 to 485 µm after one week (p = 0.374) and further to 299 µm after 12 months (p = 0.345). There was an overall significant decrease in CRT development from injection until month 12 (p = 0.030).

Conclusion

Intravitreally injected Actilyse® might have the potential to induce PVD in eyes with recent onset of RVO and might favorably impact standard treatment regimens. A prospective and randomized clinical trial is needed to prove this hypothesis.
Vorheriger Artikel Study of foveal avascular zone by OCTA before and after idiopathic epiretinal membrane removal
Nächster Artikel Autosomal-dominante Optikusatrophie
Literatur
1.
Bertelmann T, Kičová N, Messerschmidt-Roth A, Irle S, Sekundo W, Mennel S. The vitreomacular interface in retinal vein occlusion. Acta Ophthalmol. 2011;89:e327–e31.PubMed
2.
3.
Hikichi T, Konno S, Trempe CL. Role of the vitreous in central retinal vein occlusion. Retina. 1995;15:29–33.PubMed
4.
Takahashi MK, Hikichi T, Akiba J, Yoshida A, Trempe CL. Role of the vitreous and macular edema in branch retinal vein occlusion. Ophthalmic Surg Lasers. 1997;28:294–9.PubMed
5.
Akiba J, Kado M, Kakehashi A, Trempe CL. Role of the vitreous in posterior segment neovascularization in central retinal vein occlusion. Ophthalmic Surg. 1991;22:498–502.PubMed
6.
Kado M, Jalkh AE, Yoshida A, Takahashi M, Wazen N, Trempe CL, Schepens CL. Vitreous changes and macular edema in central retinal vein occlusion. Ophthalmic Surg. 1990;21:544–9.PubMed
7.
Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol. 1999;97:465–9.PubMed
8.
Charbonnel J, Glacet-Bernard A, Korobelnik JF, Nyouma-Moune E, Pournaras CJ, Colin J, Coscas G, Soubrane G. Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol. 2004;242:223–8.PubMed
9.
Avunduk AM, Cetinkaya K, Kapicioğlu Z, Kaya C. The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand. 1997;75:441–2.PubMed
10.
Noma H, Funatsu H, Mimura T, Shimada K. Visual acuity and foveal thickness after vitrectomy for macular edema. Ophthalmologica. 2010;224:367–73.PubMed
11.
Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series. BMC Ophthalmol. 2010;10:11.PubMedPubMedCentral
12.
Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, Group M. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367:606–15.PubMed
13.
DOG, Retinologische Gesellschaft, BVA. Durchführung von intravitrealen Injektionen (IVI). Empfehlung der DOG, der Retinologischen Gesellschaft und des BVA. (Juli 2007).
14.
Kičová N, Bertelmann T, Irle S, Sekundo W, Mennel S. Evaluation of a posterior vitreous detachment: a comparison of biomicroscopy, b‑scan ultrasonography and optical coherence tomography to surgical findings with chromodissection. Acta Ophthalmol. 2012;90:e264–e8.PubMed
15.
Gandorfer A. Pharmacologic vitreolysis. Dev Ophthalmol. 2007;39:149–56.PubMed
16.
Murakami T, Takagi H, Ohashi H, Kita M, Nishiwaki H, Miyamoto K, Watanabe D, Sakamoto A, Yamaike N, Yoshimura N. Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina. 2007;27:1031–7.PubMed
17.
Murakami T, Takagi H, Kita M, Nishiwaki H, Miyamoto K, Ohashi H, Watanabe D, Yoshimura N. Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;142:318–20.PubMed
18.
Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000;84:609–13.PubMedPubMedCentral
19.
Bertelmann T, Mennel S, Sekundo W, Strodthoff S, Witteborn MC, Stief T, Nguyen N, Koss MJ. Intravitreal functional plasminogen is elevated in central retinal vein occlusion. Ophthalmic Res. 2013;50:151–9.PubMed
20.
21.
Bertelmann T, Sekundo W, Strodthoff S, Witteborn MC, Stief T, Irle S, Nguyen N, Koss MJ, Mennel S. Intravitreal functional plasminogen in eyes with branch retinal vein occlusion. Ophthalmic Res. 2014;52:74–80.PubMed
22.
23.
Gutman FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol. 1984;28(Suppl):462–70.PubMed
24.
Ghazi NG, Noureddine B, Haddad RS, Jurdi FA, Bashshur ZF. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina. 2003;23:780–4.PubMed
25.
Tagami M, Kusuhara S, Imai H, Honda S, Tsukahara Y, Negi A. Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion. Ophthalmologica. 2011;226:81–6.PubMed
26.
Yamamoto T, Kamei M, Kunavisarut P, Suzuki M, Tano Y. Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model. Graefes Arch Clin Exp Ophthalmol. 2008;246:509–14.PubMed
27.
Murakami T, Tsujikawa A, Ohta M, Miyamoto K, Kita M, Watanabe D, Takagi H, Yoshimura N. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol. 2007;143:171–3.PubMed
28.
Rowley SA, Vijayasekaran S, Yu PK, McAllister IL, Yu DY. Retinal toxicity of intravitreal tenecteplase in the rabbit. Br J Ophthalmol. 2004;88:573–8.PubMedPubMedCentral
29.
Chen SN, Yang TC, Ho CL, Kuo YH, Yip Y, Chao AN. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology. 2003;110:704–8.PubMed
30.
Jaffe GJ, Green GD, McKay BS, Hartz A, Williams GA. Intravitreal clearance of tissue plasminogen activator in the rabbit. Arch Ophthalmol. 1988;106:969–72.PubMed
31.
Weber-Krause B, Eckardt C. incidence of posterior vitreous detachment in the elderly. Ophthalmologe. 1997;94:619–23.PubMed
32.
Geck U, Pustolla N, Baraki H, Atili A, Feltgen N, Hoerauf H. Posterior vitreous detachment following intravitreal drug injection. Graefes Arch Clin Exp Ophthalmol. 2013;251:1691–5.PubMedPubMedCentral
33.
Elman MJ, Raden RZ, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc. 2001;99:219–21, discussion 222–213.PubMedPubMedCentral
34.
Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999;30:427–34.PubMed
35.
Figueroa MS, Ruiz Moreno JM. bravo and cruise: Ranibizumab for the treatment of macular edema secondary to retinal vein occlusion. Arch Soc Esp Oftalmol. 2012;87(Suppl 1):46–53.PubMed
36.
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, Group GS. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 galileo study. Am J Ophthalmol. 2014;158:1032–1038.e1032.PubMed
37.
Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Group OGS. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.e1133.PubMed
38.
Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J, Group OGS. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–60.PubMed
39.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.PubMed
40.
McAllister IL, Vijayasekaran S, Yu DY. Intravitreal tenecteplase (metalyse) for acute management of retinal vein occlusions. Invest Ophthalmol Vis Sci. 2013;54:4910–8.PubMed
41.
Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol. 1999;128:739–46.PubMed
42.
Mahmoud TH, Peng YW, Proia AD, Davidson M, Deramo VA, Fekrat S. Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion. Br J Ophthalmol. 2006;90:911–5.PubMedPubMedCentral
43.
Üney G, Ünlü N, Acar MA, Hazirolan D, Altiparmak UE, Yalniz-Akkaya Z, Örnek F. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration. Retina. 2014;34:32–7.PubMed
44.
de Smet MD, Gad Elkareem AM, Zwinderman AH. The vitreous, the retinal interface in ocular health and disease. Ophthalmologica. 2013;230:165–78.PubMed
45.
Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, Abdelfattah N, Kuppermann B, Csaky KG, D’Argenio DZ, Burke JA, Hughes PM, Robinson MR. Vitreous vegf clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135–8.PubMed
46.
Gandorfer A, Putz E, Welge-Lüssen U, Grüterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol. 2001;85:6–10.PubMedPubMedCentral
47.
Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690–6.PubMed
Metadaten
Titel
Intravitreal Actilyse® injection to induce posterior vitreous detachment in eyes with recent onset of retinal vein occlusion
A retrospective evaluation
verfasst von
Thomas Bertelmann
Stefan Strodthoff
Walter Sekundo
Stefan Mennel
Publikationsdatum
03.08.2017
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 1/2018
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-017-0351-z

Weitere Artikel der Ausgabe 1/2018

Pharmacologic vitreolysis for vitreomacular traction syndrome and macular hole

  • main topic

Vitreoretinal Disorders and Vitrectomy

  • editorial

Study of foveal avascular zone by OCTA before and after idiopathic epiretinal membrane removal

  • Vitreoretinal Disorders and Vitrectomy

Vitreous and macular hole: genesis and nemesis

  • Vitreoretinal Disorders and Vitrectomy

Hybrid 20/23-gauge vitrectomy in a patient with retained intraocular air-gun pellet

  • Vitreoretinal Disorders and Vitrectomy

Harvey A. Lincoff, MD

  • obituary